Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized rATG for GVHD Prevention in Haplo-HSCT
NCT05634915Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Cumulative incidence of acute Graft-Versus-Host Disease at 100 days and CD4+ immune reconstitution at 3 months. Status: unknown.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05634915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634915.